Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (5) ·
Adenosine receptor antagonist (1) ·
Adenosine receptor antagonist; dopaminergic (1) ·
Adenosine receptor antagonist; phosphodiesterase inhibitor (1) ·
Alpha-adrenergic agonist; monoamine releaser (1) ·
Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1) ·
AMPA modulator; catecholaminergic (1) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
Dopamine and serotonin reuptake inhibitor; actoprotector (1) ·
Dopamine reuptake inhibitor; tropane analogue (1) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Indirect sympathomimetic; norepinephrine releaser (1) ·
Monoamine releasing agent (8) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Monoamine reuptake inhibitor; sodium channel blocker (1) ·
N-methyl analogue of 2-AI (1) ·
Nicotinic acetylcholine receptor agonist (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine releaser (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Norepinephrine–dopamine reuptake inhibitor (2) ·
Potent dopamine and norepinephrine reuptake inhibitor (1) ·
Potent dopamine/norepinephrine reuptake inhibitor (1) ·
Selective norepinephrine reuptake inhibitor (1) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Trace amine-associated receptor 1 (TAAR1) agonist; monoamine releaser (1) ·
'"`UNIQ--vote-00000013-QINU`"' Does not stimulate insulin secretion; minimal hypoglycemia risk as monotherapy. Cleared renally unchanged; dose-adjust by eGFR'"`UNIQ--ref-00000014-QINU`"'. Rare lactic acidosis primarily in renal failure or acute illness. (1) ·
'"`UNIQ--vote-000002D7-QINU`"' Hypoglycemia is the central risk, especially in elderly and renally impaired patients (glipizide has shorter half-life than glyburide, which is one reason it is preferred in older adults). CYP2C9 substrate; weight gain typical. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
uses:
None (43) ·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"', '"`UNIQ--vote-00000017-QINU`"' (1) ·
'"`UNIQ--vote-00000278-QINU`"', '"`UNIQ--vote-00000279-QINU`"', '"`UNIQ--vote-0000027A-QINU`"', '"`UNIQ--vote-0000027B-QINU`"' (1) ·
'"`UNIQ--vote-000002D8-QINU`"' (1) ·
'"`UNIQ--vote-00000491-QINU`"' (1) ·
'"`UNIQ--vote-0000054E-QINU`"', '"`UNIQ--vote-0000054F-QINU`"', '"`UNIQ--vote-00000550-QINU`"', '"`UNIQ--vote-00000551-QINU`"' (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-00000822-QINU`"', '"`UNIQ--vote-00000823-QINU`"' (1) ·
'"`UNIQ--vote-0000117B-QINU`"' (1)
starting dose:
None (43) ·
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
10 mg PO once daily in the morning; 5 mg starting in heart failure (1) ·
10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
15-30 mg PO once daily; titrate to 45 mg (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
5 mg PO once daily, 30 minutes before breakfast; XL: 5 mg with breakfast (1) ·
500 mg PO once or twice daily with meals; titrate weekly to limit GI effects (1)
preparations:
None (43) ·
1 mg, 2 mg, 4 mg tablets (1) ·
10 mg, 25 mg tablets (1) ·
15, 30, 45 mg tablets (1) ·
25, 50, 100 mg tablets; combination tablets with metformin (1) ·
5 mg tablets; combination with metformin (1) ·
5 mg, 10 mg immediate-release tablets; 2.5 mg, 5 mg, 10 mg extended-release tablets (1) ·
5 mg, 10 mg tablets (1) ·
500 mg, 850 mg, 1000 mg IR tablets; 500 mg, 750 mg, 1000 mg ER tablets; 500 mg/5 mL oral solution (1)
fda max:
onset:
None (43) ·
1-2 hours (1) ·
Glucose lowering within days; HbA1c effect at 8-12 weeks (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; cardiovascular and renal benefits over months (1) ·
Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) ·
HbA1c effect at 12-16 weeks (slower than other classes) (1) ·
Postprandial glucose effect within days; HbA1c by 12 weeks (2) ·
Within 30 minutes (IR) (1)
duration:
halflife:
None (43) ·
2-5 hours'"`UNIQ--ref-000002D9-QINU`"' (1) ·
6.2 hours (plasma); ~17 hours in erythrocytes'"`UNIQ--ref-00000018-QINU`"' (1) ·
~12 hours (effective); terminal much longer'"`UNIQ--ref-0000117C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-0000027C-QINU`"' (1) ·
~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) ·
~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1) ·
~3-7 hours (parent); 16-24 hours including active metabolites'"`UNIQ--ref-00000824-QINU`"' (1) ·
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1)
bioavailability:
None (43) ·
50-60% (oral; decreased with food, but food given anyway for GI tolerance)'"`UNIQ--ref-00000019-QINU`"' (1) ·
High (oral; absorption not affected by food)'"`UNIQ--ref-00000825-QINU`"' (1) ·
High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"' (1) ·
~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"' (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"' (1) ·
~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) ·
~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
pregnancy:
None (43) ·
Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Avoid; switch to insulin. Hypoglycemia in newborn reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used in PCOS and gestational diabetes; placental transfer occurs.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)
Showing below up to 51 results in range #1 to #51.